Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Scripps Translational Science Institute Navigenics, Inc. Affymetrix, Inc. Mircrosoft Corp. |
---|---|
Information provided by: | Scripps Translational Science Institute |
ClinicalTrials.gov Identifier: | NCT00808587 |
The specific aims for this project are to enroll up to 10,000 subjects who will have their genomes surveyed using the Navigenics™ Health Compass technology. The Navigenics Health Compass helps you understand what your genetic variants have to say about the future of your health, and gives you action steps to take control of your health today. In addition, the investigators will assess how the Navigenics Health Compass, results affect lifestyle decisions. The phenotyping information that can be analyzed with the resulting Navigenics genotype information will assist in identifying genetic variations associated with other traits and diseases.
The uses of molecular markers such as cholesterol and glucose levels to assess disease risk are well established in clinical medicine today. Although these tools are useful in screening for subclinical disease, their predictive value is limited. Until recently, these molecular markers were the best risk assessment and screening tools in existence. Since the completion of the Human Genome Project, the era of personalized medicine, which exploits knowledge of the genes an individual carries that may predispose him/her to disease, has come to the forefront of research.
The Navigenics Health Compass technology assesses risk for about over 20 common diseases and provides subjects with more accurate assessments of their individual predictive risk for developing these conditions than traditional biomarkers such as cholesterol and glucose levels. This may positively influence changes in lifestyle, as well as decisions to seek further medical evaluation associated with preventive strategies.
Condition |
---|
Genes |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Scripps Genomics Health Initiative |
Estimated Enrollment: | 10000 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
No Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Scripps Health employees, friends and family
Inclusion Criteria:
Exclusion Criteria:
Contact: Laura Ornowski, NP | 858-554-5736 | ornowski.laura@scrippshealth.org |
United States, California | |
Scripps Health | Recruiting |
San Diego, California, United States, 92037 |
Principal Investigator: | Eric J. Topol, MD | Scripps Translational Science Institute |
Responsible Party: | Scripps Translational Science Institute (STSI) ( Eric Topol, MD ) |
Study ID Numbers: | HSC# 08-5069 |
Study First Received: | December 9, 2008 |
Last Updated: | December 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00808587 |
Health Authority: | United States: Institutional Review Board |
Genomic Scan Personalized Medicine Gene testing |